0001193125-21-316248.txt : 20211102 0001193125-21-316248.hdr.sgml : 20211102 20211102080805 ACCESSION NUMBER: 0001193125-21-316248 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20211101 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211102 DATE AS OF CHANGE: 20211102 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Codiak BioSciences, Inc. CENTRAL INDEX KEY: 0001659352 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39615 FILM NUMBER: 211369343 BUSINESS ADDRESS: STREET 1: 35 CAMBRIDGEPARK DRIVE STREET 2: SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 BUSINESS PHONE: 617-949-4100 MAIL ADDRESS: STREET 1: 35 CAMBRIDGEPARK DRIVE STREET 2: SUITE 500 CITY: CAMBRIDGE STATE: MA ZIP: 02140 FORMER COMPANY: FORMER CONFORMED NAME: Codiak Biosciences, Inc. DATE OF NAME CHANGE: 20151125 8-K 1 d193591d8k.htm 8-K 8-K
false 0001659352 0001659352 2021-11-01 2021-11-01

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (date of earliest event reported)

November 1, 2021

 

 

Codiak BioSciences, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-39615   47-4926530

(State or other jurisdiction of

incorporation or organization)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification Number)

35 CambridgePark Drive, Suite 500

Cambridge, MA 02140

(Address of principal executive offices and zip code)

(617) 949-4100

(Registrant’s telephone number, including area code)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

  ☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

   

Trading

symbol(s)

   

Name of each exchange

on which registered

Common Stock, par value $0.0001 per share    CDAK    Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

Item 1.01

Entry into a Material Definitive Agreement.

On November 1, 2021, Codiak BioSciences, Inc. (the “Company”) and Lonza Rockland, Inc. (“Lonza”) entered into an Asset Purchase Agreement (the “APA”) pursuant to which Lonza will acquire Codiak’s exosome manufacturing facility and related assets, and sublease the premises, located at 4 Hartwell Place, Lexington, MA 02421. As consideration for the asset purchase, the Company shall receive approximately $65.0 million worth of exosome manufacturing services for its clinical programs for four years. The closing is expected to occur within two weeks of the execution of the APA (the “Closing”). At the Closing, it is expected that certain specialized manufacturing and quality personnel of the Company will become employees of Lonza.

In connection with, and as consideration for the APA, at the Closing, the Company and Lonza shall enter into a Manufacturing Services Agreement (the “MSA”). Pursuant to the MSA, Lonza will become the exclusive manufacturing partner for future clinical and commercial manufacturing of the Company’s exosome products pipeline.

In connection with, and at the Closing, the Company and Lonza shall enter into a Licensing and Collaboration Agreement (the “License”). Pursuant to the License, the Company shall grant Lonza a worldwide, exclusive and sub-licensable license to the Company’s high-throughput exosome manufacturing intellectual property in the contract development and manufacturing field. Pursuant to the License, the Company is eligible to receive from Lonza a double-digit percentage of future sublicensing revenues. The Company shall retain its pipeline of therapeutic candidates and core exosome engineering, drug-loading expertise and related intellectual property. The companies will collaborate to establish a joint Center of Excellence for further development of exosome manufacturing technology, with a shared oversight committee. The Center of Excellence will leverage the strengths of both companies to pursue developments in exosome production, purification and analytics.

The foregoing summaries of certain terms of the APA, MSA and License do not purport to be complete and are subject to, and are qualified in their entirety by, the full text of the APA, MSA and License, which the Company plans to file as exhibits to its Annual Report on Form 10-K for the year ending December 31, 2021 and are incorporated by reference herein.

A press release announcing the foregoing transactions is attached hereto as Exhibit 99.1.

Item 9.01 - Financial Statements and Exhibits

(d) Exhibits

 

Exhibit
Number

   

Description

99.1    Press release, dated November 2, 2021, by Codiak BioSciences, Inc. and Lonza Rockland, Inc.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

Date: November 2, 2021

     Codiak BioSciences, Inc.
    By:  

/s/ Douglas E. Williams

    Name:   Douglas E. Williams, Ph.D.
    Title:   Chief Executive Officer and President
 EX-99.1 2 d193591dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

 

News Release

    

LOGO

 

LOGO

 

Lonza to Acquire Codiak BioSciences Exosomes Manufacturing Facility and Establish a Long-Term Strategic Collaboration

 

  •  

Lonza to acquire and operate Codiak’s Lexington, MA (US) facility and become the strategic manufacturing partner for Codiak’s pipeline

 

  •  

Lonza and Codiak to establish a Center of Excellence focused on exosome manufacturing and characterization technologies

 

  •  

Lonza to gain access to the worldwide, exclusive and sub-licensable rights of Codiak’s high-throughput exosome manufacturing technology

 

  •  

Codiak to receive approximately $65 million of in-kind manufacturing services for its clinical-stage programs and retain core exosome engineering and loading expertise

 

 

Basel, Switzerland and Cambridge (MA), USA, 02 November 2021 – Lonza, a global manufacturing partner to the pharma, biotech and nutrition industries, announced today the acquisition of an exosome manufacturing facility located in Lexington, Massachusetts (US) from Codiak BioSciences, a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics.

Codiak will retain its pipeline of therapeutic candidates as well as its exosome engineering and drug-loading technologies. Codiak will receive as part of the deal approximately $65 million of cGMP manufacturing services in kind. Lonza will gain worldwide access and sub-licensable rights to Codiak’s high-throughput perfusion-based cGMP process for exosome manufacturing.

The companies will establish a Center of Excellence for the development of exosome manufacturing technologies. The Center of Excellence will leverage the strengths of both companies to advance developments in exosome production, purification and analytics while providing Lonza customers with exosome assay and process development, analytics and manufacturing services.

Alberto Santagostino, SVP, Head of Cell and Gene Technologies at Lonza, commented: “We are excited about the collaboration we have established with Codiak BioSciences. Exosomes are emerging as a new modality for advanced therapies and could become the next frontier in biotherapeutics. Our collaboration with Codiak, one of the most advanced companies in this modality, is consistent with our strategy to advance this technology and will drive the advancement of the whole industry. We are committed to providing our capabilities to Codiak, alongside other customers in the exosome space.”

Doug Williams, PhD, CEO, Codiak BioSciences, added: “Creating an exosome manufacturing Center of Excellence with Lonza, a leading global contract development manufacturing organization, accelerates productivity of our manufacturing platform and facilitates realization of its full potential by leveraging Lonza capabilities. Importantly for Codiak, this collaboration solidifies our capacity for expanded late-stage clinical and eventually commercial manufacturing as we advance our growing clinical pipeline. We are proud Lonza recognized Codiak’s pioneering work in the manufacture of engineered exosomes and look forward to our Center of Excellence helping to set new standards for the field.”

 

 

1 / 3

 

News Release

    

LOGO

 

LOGO

 

Exosomes are nano-sized membrane vesicles secreted by many cell types, which play a role in cell-to-cell communication. They represent clinically valuable tools for various applications, ranging from early detection, diagnosis, prognosis and targeted treatments. Further development of the exosome platform also has the potential to make cell and gene therapies available and commercially viable for large patient populations.

While the development of exosomes is still at an early stage, exosome-related technologies have been progressing rapidly in the past years, with many developers working to demonstrate the efficacy and the potential of exosome-based therapies in pre-clinical or early clinical stages. Codiak has already advanced two engineered exosome therapeutic candidates into clinical studies in patients, with an IND filing planned for a third candidate in the fourth quarter of 2021.

The investment in this emerging area reflects Lonza’s strategy to differentiate through innovation. From the development of the exosome modality to the industrial production of mRNA vaccines and supporting the manufacture of live biotherapeutics, Lonza operates at the cutting edge of manufacturing technology to help customers deliver innovative new therapies to patients worldwide.

To learn more about Lonza’s exosome-related services, visit: https://pharma.lonza.com/technologies-products/exosomes

About Lonza

Lonza is the preferred global partner to the pharmaceutical, biotech and nutrition markets. We work to enable a healthier world by supporting our customers to deliver new and innovative medicines that help treat a wide range of diseases. We achieve this by combining technological insight with world-class manufacturing, scientific expertise and process excellence. Our unparalleled breadth of offerings enables our customers to commercialize their discoveries and innovations in the healthcare sector.

Founded in 1897 in the Swiss Alps, today, Lonza operates across five continents. With approximately 15,000 full-time employees, we comprise high-performing teams and individual talent that make a meaningful difference to our own business, as well as to the communities in which we operate. The company generated sales of CHF 2.5 billion with a CORE EBITDA of CHF 847 million in H1 2021. Find out more at www.lonza.com.

Follow @Lonza on LinkedIn

Follow @LonzaGroup on Twitter

About Codiak BioSciences

Codiak (NASDAQ: CDAK) is a clinical-stage biopharmaceutical company focused on pioneering the development of exosome-based therapeutics, a new class of medicines with the potential to transform the treatment of a wide spectrum of diseases with high unmet medical need. By leveraging the biology of exosomes as natural intercellular transfer mechanisms, Codiak has developed its proprietary engEx™ Platform to expand upon the innate properties of exosomes to design, engineer and manufacture novel exosome therapeutic candidates. Codiak has utilized its engEx Platform to generate a deep pipeline of engineered exosomes aimed at treating a broad range of disease areas, spanning oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease.

 

 

2 / 3

 

News Release

    

LOGO

 

LOGO

 

Lonza Contact Details

Victoria Morgan

Head of External Communications

Lonza Group Ltd

Tel +41 61 316 2283

victoria.morgan@lonza.com

Dirk Oehlers

Investor Relations

Lonza Group Ltd

Tel +41 61 316 8540

dirk.oehlers@lonza.com

Codiak Contact Details

Christopher Taylor

VP, Investor Relations and Corporate Communications

Tel +1 617-949-4220

investor@codiakbio.com

Lindy Devereux

Scient PR

Tel +1 646-515-5730

media@codiakbio.com

Additional Information and Disclaimer

Lonza Group Ltd has its headquarters in Basel, Switzerland, and is listed on the SIX Swiss Exchange. It has a secondary listing on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Lonza Group Ltd is not subject to the SGX-ST’s continuing listing requirements but remains subject to Rules 217 and 751 of the SGX-ST Listing Manual.

Certain matters discussed in this news release may constitute forward-looking statements. These statements are based on current expectations and estimates of Lonza Group Ltd, although Lonza Group Ltd can give no assurance that these expectations and estimates will be achieved. Investors are cautioned that all forward-looking statements involve risks and uncertainty and are qualified in their entirety. The actual results may differ materially in the future from the forward-looking statements included in this news release due to various factors. Furthermore, except as otherwise re-quired by law, Lonza Group Ltd disclaims any intention or obligation to update the statements contained in this news release.

Forward-Looking Statements (Codiak)

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, among other things, statements concerning the development and therapeutic potential of the Company’s engEx Platform, engEx product candidates and engineered exosomes generally, including future development plans, regulatory filings, data releases and timing with respect thereto. Any forward-looking statements in this press release are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. For a discussion of these risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Codiak’s Annual Report on Form 10-K for the year ended December 31, 2020, and in subsequent filings with the Securities and Exchange Commission, as well as discussions of potential risks, uncertainties and other important factors in Codiak’s subsequent filings with the Securities and Exchange Commission. All information in this press release is current as of the date of this report, and Codiak undertakes no duty to update this information unless required by law.

 

 

3 / 3

EX-101.SCH 3 cdak-20211101.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 cdak-20211101_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 cdak-20211101_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g193591g1102073044678.jpg GRAPHIC begin 644 g193591g1102073044678.jpg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end GRAPHIC 7 g193591g1102073045006.jpg GRAPHIC begin 644 g193591g1102073045006.jpg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end XML 8 d193591d8k_htm.xml IDEA: XBRL DOCUMENT 0001659352 2021-11-01 2021-11-01 false 0001659352 8-K 2021-11-01 Codiak BioSciences, Inc. DE 001-39615 47-4926530 35 CambridgePark Drive Suite 500 Cambridge MA 02140 (617) 949-4100 false false false false Common Stock, par value $0.0001 per share CDAK NASDAQ true false XML 9 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 01, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001659352
Document Type 8-K
Document Period End Date Nov. 01, 2021
Entity Registrant Name Codiak BioSciences, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39615
Entity Tax Identification Number 47-4926530
Entity Address, Address Line One 35 CambridgePark Drive
Entity Address, Address Line Two Suite 500
Entity Address, City or Town Cambridge
Entity Address, State or Province MA
Entity Address, Postal Zip Code 02140
City Area Code (617)
Local Phone Number 949-4100
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.0001 per share
Trading Symbol CDAK
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period false
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d193591d8k.htm cdak-20211101.xsd cdak-20211101_lab.xml cdak-20211101_pre.xml d193591dex991.htm http://xbrl.sec.gov/dei/2020-01-31 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d193591d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d193591d8k.htm" ] }, "labelLink": { "local": [ "cdak-20211101_lab.xml" ] }, "presentationLink": { "local": [ "cdak-20211101_pre.xml" ] }, "schema": { "local": [ "cdak-20211101.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cdak", "nsuri": "http://www.codiakbio.com/20211101", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d193591d8k.htm", "contextRef": "duration_2021-11-01_to_2021-11-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d193591d8k.htm", "contextRef": "duration_2021-11-01_to_2021-11-01", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://www.codiakbio.com//20211101/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0001193125-21-316248-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-316248-xbrl.zip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